iMedix Medical Content Engine 3.13.37
Home/Drugs/Lady Era

Lady Era: Uses, Dosage & Safety Information

Lady Era

Lady Era
Lady Era Tablets
1 / 2

Lady Era

Sildenafil citrate
Lady Era is a branded generic tablet containing 100 mg of sildenafil citrate, marketed to women for sexual arousal difficulties. No medicines regulator has approved sildenafil for this use. It contains the same active ingredient as Viagra, at the maximum single dose, sold without the prescribing checks that apply to approved sildenafil.
  • ActiveIngredient: Sildenafil citrate
  • DosageForm: Film-coated oral tablet
  • Dosage: 100 mg
  • Indications: Marketed for female sexual arousal difficulties. No FDA-approved indication in women.
  • Manufacturer: Various generic manufacturers
  • Storage: Store at 15-30 C (59-86 F). Protect from moisture and light.
  • Drug Status: Not Approved
Drug Status: Not Approved
Description
Regulatory status
Not approved by the FDA, EMA or MHRA for use in women.
Sildenafil is approved for other conditions. This product, and this use, are not.

What is Lady Era?

Lady Era is a branded generic tablet containing 100 mg of sildenafil citrate, the same phosphodiesterase type 5 inhibitor used in erectile dysfunction medicines. It is not FDA-approved for any indication in women. The pink colouring and the brand name are marketing choices, not a different formulation.

How it works

Sildenafil blocks the PDE5 enzyme, which increases blood flow to genital tissue during sexual stimulation.1 The effect is vascular only. It does not create desire, act on brain chemistry, or treat low libido — a distinction that determines whether this medicine can address a given problem at all.

Clinical details

Sildenafil selectively inhibits cGMP-specific PDE5, the enzyme responsible for cGMP degradation in smooth muscle. Inhibition sustains cGMP levels, producing smooth muscle relaxation and increased arterial inflow. In genital tissue the same mechanism described in men is presumed to operate in women, but the downstream relationship between increased blood flow and reported arousal has not been established in controlled studies.3

Regulatory position

No medicines regulator has approved sildenafil for female sexual dysfunction. Products marketed under the Lady Era name have not been through any approval process for this indication.

General Instructions

How to Take Lady Era

There is no approved dosing schedule for sildenafil in women. The guidance below describes how sildenafil is taken in its approved uses and is provided for context only.

Timing and administration

Sildenafil tablets are swallowed whole with water, with or without food. A high-fat meal delays onset.1 In approved use the tablet is taken 30 to 60 minutes before anticipated activity, and sexual stimulation is required for any effect.

Frequency

  • Not more than one tablet in any 24-hour period.
  • Not intended for daily use.
  • A second tablet does not increase benefit and does increase risk.

A note on the 100 mg strength

Lady Era is sold only at 100 mg. In approved male use, prescribers typically start at 25 mg or 50 mg to assess tolerance and reserve 100 mg as the maximum single dose.1 Starting at the maximum, in a population where no dose-finding work has been done, has no clinical rationale.

Side Effects

Side Effects of Lady Era

The side effect profile is that of sildenafil. The frequencies below come from placebo-controlled trials in men taking 100 mg for erectile dysfunction, because no comparable trial data exist in women.1 That is itself a limitation — see Evidence Scope below. For a broader account of what these effects feel like in practice, see what is known about sildenafil in women.

Reported Side Effects of Sildenafil
FrequencyEffectNotes
Very common (over 1 in 10)HeadacheReported in about 16% of participants at 100 mg.
Common (1 in 100 to 1 in 10)Facial flushing (about 10%), indigestion (about 7%), nasal congestion (about 4%), altered vision (about 3%)Vascular effects; usually mild and time-limited.
CommonDizziness, back pain, muscle achesDizziness matters more where blood pressure is already low.
Rare (under 1 in 1000)Priapism, sudden vision loss, sudden hearing lossRequire emergency assessment.
Emergency — stop and seek care
Get immediate medical attention if you experience any of the following
  • Prolonged, painful genital engorgement lasting more than four hours (priapism)
  • Sudden loss of vision in one or both eyes
  • Sudden reduction or loss of hearing, with or without ringing in the ears (tinnitus)
  • Chest pain, severe dizziness or nausea during sexual activity
  • Difficulty breathing, or swelling of the face, lips, tongue or throat
Uses

What is Lady Era Used For?

Lady Era is marketed for female sexual arousal disorder, meaning difficulty with the physical side of arousal. It has no approved indication in any jurisdiction.

What the marketing claims

The stated premise is that increased genital blood flow improves sensitivity and lubrication. This premise is plausible pharmacologically. Whether it produces a benefit women actually notice is a separate question, and one the evidence has not settled. The question is examined in more detail in whether women can take Viagra.

What it cannot do

  • It does not affect desire. Low libido is a different problem with different biology. The medicine approved for it, Addyi (flibanserin), acts on brain chemistry rather than blood vessels.
  • It does not address underlying causes. Sexual difficulties are frequently hormonal, psychological, relational, or a side effect of another medicine.
  • It is not a diagnosis. Arousal difficulty can be the presenting sign of a treatable condition.

Approved sildenafil indications

Sildenafil is approved for erectile dysfunction in men and, as Revatio, for pulmonary arterial hypertension in adults of either sex.1 Neither approval covers sexual dysfunction in women.

Safety advice

Interactions Alcohol:

Unsafe
Alcohol adds to the blood-pressure-lowering effect of sildenafil, increasing dizziness, headache and the risk of fainting. It also blunts sexual response, working against any effect the medicine might have.

Interactions Other Medications:

Consult your doctor
Nitrates and riociguat are absolutely contraindicated. Alpha-blockers, potent CYP3A4 inhibitors and other antihypertensives require assessment. A full medicines review is essential before use. See Interactions for the full table.

Special Groups Pregnancy:

Unsafe
Sildenafil has no established safety profile in pregnancy for this use and should not be taken while pregnant. Arousal difficulty during pregnancy warrants a clinical conversation, not self-medication.

Special Groups Breastfeeding:

Unsafe
It is not established whether sildenafil passes into breast milk in clinically relevant amounts. It should not be used while breastfeeding.

Special Groups Elderly:

Use with caution
Clearance falls with age and plasma exposure rises, increasing the risk of hypotension and dizziness. In approved use a reduced starting dose is considered; a fixed 100 mg product allows no such adjustment.

Special Groups Children:

Unsafe
Not intended for anyone under 18 years of age under any circumstances.

Effects on Activities Driving:

Use with caution
Dizziness, blurred vision and altered colour perception can occur. Do not drive until you know how the medicine affects you.

Effects on Activities Operating Machinery:

Use with caution
The same precautions apply as for driving. Avoid machinery and tasks requiring full alertness until individual response is known.
Concerns

Important Safety Concerns and Considerations

Regulatory status

The FDA has not approved sildenafil for any indication in women. Neither has the EMA nor the MHRA — meaning there is no jurisdiction in which this product is legitimately approved for the purpose it is sold for.1

Sildenafil itself is approved in the United States for two uses: erectile dysfunction in men, and pulmonary arterial hypertension in adults of either sex, marketed as Revatio. The gap is the indication, not the molecule.

Product authenticity

Lady Era is sold predominantly online without a prescription, outside regulated pharmacy supply. Products obtained this way may contain a different quantity of active ingredient than stated, a different active ingredient, or contaminants. There is no batch traceability and no route for recall.

Delayed diagnosis

Difficulty with arousal can be the first noticeable sign of diabetes, cardiovascular disease, thyroid disorder, hormonal change, depression, or an adverse effect of another prescribed medicine. Self-treating the symptom postpones identification of the cause. This is the risk least visible to the person taking the tablet and, over time, often the most consequential.

Warnings

Critical Warnings for Lady Era Use

Nitrates: absolute contraindication

Sildenafil must never be combined with any nitrate or nitric oxide donor. This includes prescribed nitrates such as nitroglycerin and isosorbide mononitrate, and recreational amyl nitrite (“poppers”). The combination can cause a life-threatening fall in blood pressure.1 See Interactions for the full list.

Cardiovascular status

Sildenafil causes vasodilation and lowers blood pressure. Sexual activity independently increases cardiac workload. The combination is inadvisable in anyone with recent myocardial infarction or stroke, unstable angina, severe heart failure, uncontrolled hypertension or hypotension.1

Do not use if you

  • take any nitrate medicine or use recreational nitrites
  • take riociguat, a soluble guanylate cyclase stimulator
  • have a known allergy to sildenafil or any tablet component
  • have retinitis pigmentosa, a rare inherited retinal disorder

Vision and hearing

Non-arteritic anterior ischaemic optic neuropathy (NAION) has been reported in temporal association with PDE5 inhibitors, as has sudden hearing loss.1 Both are rare. Both require immediate assessment. Anyone who has previously had NAION should not take sildenafil.

An unregulated supply chain

Products sold as Lady Era are not dispensed through regulated pharmacy channels in the United States or European Union. Content and purity are not verifiable.

Dosage

Lady Era Dosage Information

No regulator has established a dose of sildenafil for female sexual dysfunction. No dose-ranging study has been conducted in women for this purpose.

Sildenafil Strengths and Context
StrengthApproved contextClinical note
20 mgPulmonary arterial hypertensionThree times daily; a different indication and schedule entirely.
25 mg / 50 mgErectile dysfunction, starting dosesChosen to assess individual tolerance before escalation.
100 mg (Lady Era)Erectile dysfunction, maximum single doseThe ceiling of approved dosing, offered here as the only option.

Dose adjustment in organ impairment

In approved use, a 25 mg starting dose is considered in severe renal impairment (creatinine clearance below 30 mL/min) and in hepatic impairment (Child-Pugh A or B), because clearance is reduced and plasma exposure rises.1 A fixed 100 mg product cannot be adjusted.

Overdose

Exceeding one tablet in 24 hours does not increase benefit. It raises the risk of severe hypotension, syncope, priapism and visual disturbance. Overdose requires emergency care.

Interactions

Drug Interactions with Lady Era

Sildenafil has several clinically significant interactions. The table below rates each on two axes: severity of the potential outcome, and how well the interaction is documented in the literature — the classification scheme used by Micromedex.4 A well-documented moderate interaction and a poorly documented major one call for different decisions.

Significant Interactions with Sildenafil
Interacting substanceEffect and riskSeverityDocumentation
Nitrates — including nitroglycerin, isosorbide mononitrate and amyl nitriteSevere, potentially fatal hypotensionContraindicatedExcellent
RiociguatSymptomatic hypotensionContraindicatedGood
Alpha-blockers (tamsulosin, doxazosin)Additive blood pressure reduction, dizziness, syncopeMajorGood
Potent CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin)Markedly increased sildenafil exposure and toxicity riskMajorExcellent
Other antihypertensivesAdditive hypotensive effectModerateGood
Grapefruit juiceIncreased plasma concentration through intestinal CYP3A4 inhibitionModerateFair
AlcoholIncreased hypotension, dizziness and headacheModerateFair
Clinical details

Sildenafil is cleared principally by CYP3A4, with a minor CYP2C9 contribution. Co-administration of ritonavir 500 mg twice daily produced an eleven-fold increase in sildenafil AUC; ketoconazole and itraconazole produce smaller but clinically relevant increases. In approved use a 25 mg starting dose is advised with potent CYP3A4 inhibitors.1 A fixed-dose 100 mg product offers no way to apply that adjustment.

Tell a clinician about every prescription medicine, over-the-counter product, herbal remedy and supplement before taking sildenafil in any form.

FAQs
Yes, pharmacologically. Both contain sildenafil citrate; Lady Era contains 100 mg, the maximum single dose used in approved male treatment. The pink tablet and the brand name are marketing, not a different formulation. The meaningful difference is not the molecule but the absence of any approval, prescribing check or supply oversight.
No. Sildenafil acts on blood vessels, not on brain chemistry. Desire and arousal are separate processes with separate biology. The medicines approved for low desire in premenopausal women, flibanserin and bremelanotide, work on neurotransmitter and melanocortin pathways instead.
Because no dose-finding study has ever been done in women. In approved male use, prescribers usually start at 25 mg or 50 mg and reserve 100 mg as the ceiling. A single-strength product at that ceiling removes the ability to start low, and removes the dose adjustment that would normally apply in older age, renal impairment or alongside a CYP3A4 inhibitor.
The full approved label is published by the National Library of Medicine on DailyMed and by the EMA for European products. Those documents cover only the approved indications, erectile dysfunction and pulmonary arterial hypertension. Neither contains dosing, efficacy or safety data for use in women, because no such approval exists.
Evidence and Reported Data

Evidence Scope

What we know
  • Sildenafil inhibits PDE5 and increases genital blood flow during stimulation. The mechanism is established.1
  • The nitrate interaction is confirmed by controlled study and is potentially fatal.
  • 100 mg is the maximum single dose evaluated in approved male use.
What remains uncertain
  • Efficacy in women is unresolved. Trials of sildenafil in female sexual dysfunction have produced inconsistent results, and no adequately powered randomised trial has demonstrated a reproducible benefit.3
  • The dose is inherited, not derived. No dose-finding study has been conducted in women. The 100 mg strength comes from male erectile dysfunction dosing.
  • Adverse-effect frequencies are extrapolated. Every percentage in the side effects table comes from trials in men. Women differ in body composition and hormonal environment; whether the frequencies transfer is unknown.
  • Long-term safety in women has not been studied. No cohort has been followed for repeated use in this population.
  • Postmarketing reports cannot establish incidence. Spontaneous reporting systems can flag a potential association but carry no denominator, so a report count cannot be converted into a rate.

What has been reported to the FDA

The FDA Adverse Event Reporting System has received 126,561 reports naming sildenafil since 2004. Of these, 52,128 concern female patients. Data current to 30 July 2026.6

Reported Reactions in Women (FAERS)
Reported reactionReports
Dyspnoea (breathlessness)8,750
Headache5,997
Death4,612
Diarrhoea4,561
Nausea4,360
Fatigue3,737
Dizziness3,426
Pneumonia3,146
Cough3,114
Fluid retention2,320
How to read this table

The reactions that dominate it — breathlessness, pneumonia, cough, fluid retention, death — are not the profile of sildenafil taken for sexual arousal. Sildenafil is also marketed as Revatio for pulmonary arterial hypertension, a progressive and frequently fatal lung disease that affects women more often than men. Those patients are seriously ill, take sildenafil three times daily for years, and their reported events reflect the underlying disease at least as much as the medicine.

This is the practical limit of spontaneous reporting data: it records what was reported, not what the medicine caused, and it cannot separate one population of users from another. FAERS has no denominator, so none of these counts can be converted into a rate or a percentage. They are shown here because they are the only regulator-published safety signal that exists for sildenafil in women — and because knowing what the data cannot tell you is part of reading it honestly.

Who was this medicine studied in?

No FDA Drug Trials Snapshot exists for this product. Snapshots are published only for medicines that have completed FDA approval as a new molecular entity, and only for approvals from January 2015 onward. This product has never been through any approval process, so no regulator-published breakdown of trial participants exists.

The sildenafil programme that supported approval in men concluded in 1998, seventeen years before the Snapshots programme began. No comparable demographic transparency exists for it either.

How Lady Era compares with an approved option

One medicine is FDA-approved for hypoactive sexual desire disorder in premenopausal women. It treats desire, not arousal — and that difference is the reason the comparison matters.

Lady Era Compared with Addyi
Lady Era (sildenafil)Addyi (flibanserin)
Regulatory statusNot approved in any jurisdictionFDA-approved 2015; not authorised in the EU
TargetGenital blood flowSerotonin and dopamine pathways
AddressesPhysical arousal (claimed)Desire
Evidence baseInconsistent; no reproducible benefitPivotal trials; modest effect size
SupplyUnregulated onlinePrescription, regulated pharmacy

Full details are on the Addyi page. The transatlantic divergence on flibanserin is genuine: the FDA approved it in 2015 and it has not been authorised for the European market.

Among products marketed to women on the same premise as Lady Era, Female Cialis occupies the same position — a PDE5 inhibitor sold for an indication no regulator has approved. Among approved PDE5 inhibitors, Cialis (tadalafil) has the same approval boundary as sildenafil: approved in men, not in women.

Who this is and is not appropriate for

Not appropriate for: anyone taking nitrates or riociguat; anyone with retinitis pigmentosa or previous NAION; anyone with recent myocardial infarction or stroke, unstable angina or severe heart failure; anyone pregnant or breastfeeding; anyone under 18.

Where a clinical conversation is the right next step: persistent difficulty with arousal or desire, particularly alongside fatigue, mood change, cycle change or a recent new medicine. A gynaecologist, endocrinologist or sexual medicine specialist can identify a cause; a tablet bought online cannot.

Where to go next

References

References and Medical Sources

  1. U.S. Food and Drug Administration. Sildenafil citrate — Prescribing Information. Sections 1, 2, 4, 5.1, 5.4–5.5, 6.1, 7.1, 8.6–8.7, 12.1, 12.3.
    Revised March 2024 · Accessed 24 August 2026
    Used for: mechanism of action, approved indications, dosing and dose adjustment, contraindications, adverse reaction frequencies, CYP3A4 interaction data.
    dailymed.nlm.nih.gov
  2. Cochrane Database of Systematic Reviews. Phosphodiesterase inhibitors for female sexual dysfunction.
    Accessed 24 August 2026
    Used for: strength and consistency of efficacy evidence in women.
    cochranelibrary.com
  3. Micromedex. Drug interaction severity and documentation classification.
    Accessed 24 August 2026
    Used for: the two-axis severity and documentation ratings in the interactions table.
  4. openFDA — FDA Adverse Event Reporting System (FAERS). Drug adverse event endpoint, query on generic name “sildenafil”.
    Data through 30 July 2026 · Retrieved 24 August 2026
    Used for: total and female-subset report counts, and the ranked reaction table.
    open.fda.gov

Each numbered marker in the text above links to the source supporting that specific statement. Source revision dates are recorded so that cited sections can be re-verified at each editorial review.

Disclaimer

Disclaimer: The information on this page is provided for informational purposes only and is not medical advice. It does not replace professional medical consultation, diagnosis, or treatment. Do not self-medicate based on the information presented on this site. Always consult a doctor or other qualified healthcare professional before making any decisions about your health.

This page describes a product that has not been approved by any medicines regulator for use in women. It is published to inform, not to recommend.